China’s growing role in oncology, next-generation biologics, and high-value pipeline assets means the questions around how to engage, how to assess risk, and how to position portfolios are becoming harder to defer.
Share:
China has rapidly emerged as a source of high‑value biopharma innovation, particularly in areas like oncology and next‑generation biologics. Western pharma companies are increasingly engaging with China‑originated assets as competition intensifies and the global center of innovation continues to shift.
The webinar focuses on licensing deals, acquisitions, and evolving partnership models involving China‑owned or China‑originated assets. It also explores how deal structures are changing as NewCos and alternative development models gain traction.
The session examines the therapy areas, modalities, and mechanisms of action where China is setting the pace, using dealmaking and therapy‑area analysis to highlight where Western companies are most actively competing for assets.
This webinar is designed for professionals in portfolio strategy, business development and licensing, competitive intelligence, and investment roles at pharma and biotech companies, particularly those assessing China‑linked opportunities and risks.
Attendees will gain practical insight into how China’s role in global pharma dealmaking is evolving, how risk and value assessments are changing, and what these shifts mean for Western portfolio strategy and decision‑making.
